Shares of Biosig Technologies, Inc. (NYSE:BSGM) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokers have set a one year consensus price target of $12.58 for the company, according to Zacks. Zacks has also assigned Biosig Technologies an industry rank of 76 out of 257 based on the ratings given to its competitors.
Separately, Roth Capital reiterated a “buy” rating on shares of Biosig Technologies in a report on Thursday.
NYSE BSGM traded down $0.09 during trading hours on Friday, reaching $3.92. The company’s stock had a trading volume of 21,572 shares.
About Biosig Technologies
BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biosig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.